Gilead Sciences will invest $175 million in cash and $200 million in equity in Arcus Biosciences as part of a 10-year pact to develop cancer immunotherapies. The chemists Terry Rosen and Juan Jaen ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results